AC Immune SA (ACIU) vs Fate Therapeutics (FATE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Fate Therapeutics (FATE) has outperformed AC Immune SA (ACIU) over the past year, gaining 35.4% versus a loss of 28.2%. Over five years, ACIU leads with a -59.5% price change compared with -96.4% for FATE. Fate Therapeutics is the larger company by market cap ($261.2 million vs $248.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | FATE |
|---|---|---|
| Share price | $2.50 | $2.18 |
| Market cap | $248.57M | $261.21M |
| 1-day change | -1.96% | +2.35% |
| YTD return | -20.38% | +122.45% |
| 1-year return | -28.16% | +35.40% |
| 5-year return | -59.55% | -96.44% |
| Forward P/E | 4.20 | — |
| EPS (TTM) | $-0.53 | $-1.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.00 | $3.23 |
| 52-week low | $2.10 | $0.95 |
| Distance from 52-week high | -37.50% | -32.51% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +240.80% | +163.30% |
| Average volume | 201.86K | 1.86M |
| Shares outstanding | 99.43M | 119.82M |
| Employees | 90 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FATE has outperformed ACIU by 63.6 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees
ACIU vs FATE FAQ
Which is bigger, AC Immune SA or Fate Therapeutics?
Fate Therapeutics (FATE) is larger, with a market capitalization of $261.21M compared with $248.57M for AC Immune SA (ACIU).
Which stock has performed better over the past year, ACIU or FATE?
FATE returned +35.40% over the past 12 months, compared with -28.16% for ACIU (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Fate Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for AC Immune SA and Biotechnology: Biological Products (No Diagnostic Substances) for Fate Therapeutics.